The new Centers of Research Excellence (imCORE™) Network aims to advance promising new immuno-oncology treatments
The program is among several that Warp Drive Bio is pursuing as part of discovery efforts based on its novel Genome Mining™ technology platform
CIRM grant aims to support first-in-human trial for FT516, off-the-shelf engineered natural killer cell therapy in combination therapy for breast cancer
Initial $10 million funding will target development of at least one Phase I candidate.
Scientists at Tel Aviv University say they have developed a tool that tackles the problem of antibiotic resistance.
Nemonaxacin is in development initially for treating CAP and diabetic foot ulcers.
Metastasis in a mouse model of breast cancer inhibited by a peptide–drug conjugate that targets circulating cancer cells
Orchard Therapeutics said it will build out a gene therapy manufacturing facility in Fremont, CA, that will employ 100 people and increase its manufacturing...
Seattle Genetics retains commercialization rights in the U.S. and Canada. Takeda Pharmaceutical has exclusive commercialization rights in the rest of the world.